Professor Nutt8 Aug 2024 00:26
“We’ve been working on programmes to try to see if we can improve acute, rapid-acting treatments with ketamine and with MDMA,” explained Professor Nutt.
“There are two ways to do that. One is to develop new molecules, which is complex and expensive and needs a lot of investment. The other is to see if we can improve on the kinetics, and there are different ways of doing that.
“You can get different routes – you can go through sublingually, you can go through buccally, you could go through the skin. But those different approaches need different formulations. Graph Polymer has a nanosphere formulation that they develop, which might begin to minimize some of the peripheral metabolism of both currently existing molecules, and you could potentially reformulate MDMA or ketamine.
“If you develop new molecules, you want to optimize the kinetics, and that technology can be very helpful.”
“Optimising ketamine to make sure you get the optimal duration, speed of onset, speed of offset, and functional occupation of the brain, that’s never been done before.”
“MDMA is less challenging because currently, the MDMA treatment takes all day.
“If you’re giving someone MDMA therapy for PTSD, they come in at nine, they get the medicine at 10, and they don’t leave till five or six. That’s hugely tiring for the patient. It’s stressful for the therapists, because you have got to have someone present all the time, and no one knows whether that’s optimal.”
https://psychedelichealth.co.uk/2024/08/07/awakn-substance-use-mental-health-therapies-collaboration/
Sign In
Follow the stocks
